Join Sona Nanotech’s CEO, David Regan, and CMO, Dr. Carman Giacomantonio, for an investor webinar for an update on the development of Sona’s ‘Targeted Hyperthermia Therapy’ cancer therapy and plans for a first-in-human early feasibility study.
Don’t miss this opportunity to gain insights into Sona’s ground breaking work in the field of nanotechnology and its applications in providing a powerful tool to fight cancer.